CJC-1295: dosage in studies
Not a recommendation, not treatment guidance. This page shows only what published human studies used, with sources. This site does not say how much anyone should use of any substance. Fimea warns against using injectable peptides bought online: Fimea warning.
Published CJC-1295 doses come from two research groups. In two randomised, placebo-controlled trials in healthy adults, the substance was given under the skin as a single dose or as two or three doses [1]A. In another study, healthy men received one injection, and a follow-up study analysed blood samples from some of the same men [2, 3]B.
The CJC-1295 used in these studies binds to albumin in the blood after injection, and its half-life was 5.8-8.1 days [1]A. Doses were given once or weeks apart [1]A[2]B.
Doses used in studies
| Study | Participants | Dose | Frequency | Duration | Source and level |
|---|---|---|---|---|---|
| Teichman 2006 (two trials) | Healthy adults aged 21-61; the abstract does not give the number of participants | Four ascending dose levels under the skin; the abstract names the doses 30 and 60 µg/kg | Trial 1: single dose. Trial 2: two or three doses one or two weeks apart | The trials lasted 28 and 49 days | [1]A |
| Ionescu 2006 and Sackmann-Sala 2009 | Healthy men aged 20-40; 11 of them in the follow-up study | 60 or 90 µg/kg under the skin | Once | Measurements before the injection and one week after it | [2, 3]B |
Evidence levels: A = randomised human trial or meta-analysis · B = observational human study or case series · C = animal study · D = cell or laboratory study · E = not peer-reviewed
Units: µg = microgram, written mcg in the calculator. A milligram (mg) is a thousand times larger.
Notes
Doses are per kilogram of body weight. The injection in the Ionescu study was a single dose under the skin, as the methods of the follow-up study state [3]B.
The evidence is thin: there are three publications, from 2006-2009, the studies lasted at most 49 days and were done in healthy adults [1]A[2, 3]B.
What points the other way or is uncertain
The manufacturer's 12-week phase 2 trial in HIV patients with abdominal fat accumulation (low dose, high dose or placebo) was terminated in 2006. The registry records no reason for stopping and no results [4]E, not peer-reviewed.
In the Ionescu study, 90 µg/kg gave no different response from 60 µg/kg [2]B. In the Teichman trials the authors describe the substance as relatively well tolerated, particularly at 30 or 60 µg/kg, but the abstract does not report harms by dose [1]A.
- CJC-1295: the full substance page
- CJC-1295: why no calculator preset
- Are peptides legal in Finland?
- All dose pages and calculators
Read the research yourself: sources
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91:799-805. PMID 16352683
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91:4792-4797. PMID 17018654
- Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19:471-477. PMID 19386527
- ClinicalTrials.gov. NCT00267527: A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity (phase 2, sponsor ConjuChem, status terminated, no reason and no results recorded). Registry record, not peer-reviewed. ClinicalTrials.gov not peer-reviewed
- Dominikowski A, Rękoś Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475. PMID 42395176
Doses in the Teichman and Ionescu studies are from the abstracts. The Sackmann-Sala article and review [5] were read in full.
Content is general information about research, not medical advice. If you have symptoms, contact a healthcare professional.